Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)?

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the best hot stocks under $20 to buy. Adaptive Biotechnologies Corporation (NASDAQ:ADPT) received several bullish rating updates following its fiscal Q4 and full-year 2025 earnings release on February 5.

On February 6, TD Cowen lifted the price target on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) to $21 from $20 while maintaining a Buy rating on the shares. The rating update came after its fiscal Q4 earnings beat, with the firm raising guidance and stating that it sees confident signals on various drivers, including shift to blood-based tests, EMR integrations, new indications, community uptake, and pharma/ guidelines.

BTIG also raised the price target on Adaptive Biotechnologies Corporation (NASDAQ:ADPT) to $22 from $21 the same day, maintaining a Buy rating on the shares following the fiscal Q4 earnings release. The firm told investors in a research note that the company is firing on all cylinders and holds the position of a leading growth story in specialty labs. Adaptive Biotechnologies Corporation (NASDAQ:ADPT) also received a rating update from JPMorgan on February 6, lifting the price target on the stock to $21 from $20 and maintaining an Overweight rating on the shares.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is involved in the development of an immune medicine platform, with its services and products including immunoSEQ, clonoSEQ, cellular therapy, and vaccines.

While we acknowledge the potential of ADPT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.